| NeoLipid® DRUG DELIVERY |
|
|
|
|
NeoPharm uses novel proprietary lipids and improved procedures to entrap difficult-to-deliver drugs in small, homogenous, and stable liposomes, which are microscopic membrane-like structures created from lipids (fats). Because tumor cells need to consume large amounts of fat to sustain their rapid growth, they recognize the liposomal drug as a potential source of nutrition. NeoPharm's NeoLipid® innovative system of delivering anticancer drugs to tumors can potentially improve pharmacokinetics and reduce the toxicity of potent drugs, creating an opportunity for more comfortable-to-administer, well tolerated, and safer treatments for patients. NeoLipid® formulations are designed to produce small and homogenous drug particle sizes using simple, easy-to-use (ETU) reconstitutions of lyophilized (or freeze-dried) products with the goal of creating an extraordinarily stable liposomal product.. This is especially important during drug storage, reconstitution and administration to the patient. NeoPharm believes NeoLipid® technology may have applications in a variety of other areas in addition to the drug product candidates in clinical development. Potential advantages of NeoLipid® Drug Delivery Technology:
NeoPharm intends to explore the use of its proprietary NeoLipid® liposomal drug delivery technology in terms of life cycle management, with the goal of extending patent life and/ or modifying the pharmacokinetic profile of existing cancer drugs, and by utilizing the platform to develop new drugs. NeoPharm is aware of several widely used cancer drugs that are nearing patent expiration, as well as other widely used cancer drugs with patents that have expired. When a drug is combined with another agent or delivery system in a novel way, its patent life may be extended. Additionally, while many chemotherapeutic drugs have been effective for the treatment of cancer, these drugs have been limited in their use because of adverse side effects and difficulties in administration. NeoPharm's NeoLipid® drug delivery technology may increase the usefulness of these compounds as improved anti-cancer treatments. Finally, NeoPharm believes that its liposomal drug delivery technology may provide a platform for the development of novel therapeutic agents for cancer drug development.
|
